This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Perspective Published In The New England Journal Of Medicine Reinforces Safety Of Pradaxa® (dabigatran Etexilate Mesylate)

RIDGEFIELD, Conn., March 18, 2013 /PRNewswire/ -- A new perspective from the U.S. Food and Drug Administration (FDA) states the agency has not changed its recommendations regarding Pradaxa ® (dabigatran etexilate mesylate) capsules, following the November 2012 Mini-Sentinel evaluations. The FDA stated that bleeding rates associated with new use of PRADAXA do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY ® trial. The perspective was published online on March 13, 2013 in the New England Journal of Medicine (NEJM).

The Mini-Sentinel evaluated information about the risk of serious bleeding associated with the use of blood thinners (anticoagulants): PRADAXA and warfarin. The FDA investigated the rates of bleeding occurring in the stomach and intestines (gastrointestinal bleeding) and a type of bleeding in the brain (intracranial hemorrhage) for new users of PRADAXA compared to new users of warfarin. This assessment was done using insurance claims and administrative data from the FDA's ongoing Mini-Sentinel pilot of the Sentinel Initiative.

"We are encouraged that this article in NEJM provides important context about the safety of PRADAXA, reaffirming the findings from the pivotal RE-LY trial and the important health benefit of PRADAXA when used as directed," said Sabine Luik, M.D., Sr. Vice President, Medicine & Regulatory Affairs, U.S. Regional Medical Director, Boehringer Ingelheim Pharmaceuticals, Inc. 

About Pradaxa ® (dabigatran etexilate mesylate) CapsulesIndications and UsagePradaxa ® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

CONTRAINDICATIONSPRADAXA is contraindicated in patients with:

  • Active pathological bleeding
  • A known serious hypersensitivity reaction to PRADAXA (e.g., anaphylactic reaction or anaphylactic shock)
  • A mechanical prosthetic heart valve 

WARNINGS & PRECAUTIONS Risk of Bleeding

PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs